-
FLCN mRNA: From Variant Insight to Translation
2026-09-17
New evidence links rare FLCN variants to reduced protein expression and mTORC1 dysregulation, while showing that synthetic FLCN mRNA can restore this pathway in vitro. This article translates those findings into a practical development framework for capped mRNA production, experimental controls, and Birt-Hogg-Dubé translational strategy.
-
MLN4924 HCl salt: Applied Research Workflows
2026-09-17
MLN4924 HCl salt gives researchers a controlled way to interrogate NAE-dependent neddylation, cullin-RING ligase activity, protein turnover, and cell fate. This practical guide connects biochemical assays with viral inflammation and cancer biology research while emphasizing pilot design, controls, and troubleshooting.
-
Oxaliplatin and MDR: Designing Causal Assays
2026-09-16
Oxaliplatin research benefits from separating DNA damage, apoptosis, and transporter-mediated resistance rather than treating viability loss as a single endpoint. This article translates recent ABCB1 findings into a rigorous assay strategy for cancer chemotherapy and metastatic colorectal cancer therapy studies.
-
Poly(I:C): From dsRNA Mimic to Translational Compass
2026-09-15
Poly(I:C) is most valuable when treated as a context-dependent biological perturbation rather than a generic interferon switch. This article connects TLR3 biology with macrophage polarization, CXCL10-CXCR3 signaling, dendritic cell maturation, and translational assay design.
-
NMDA: Linking Excitotoxicity to Ferroptosis
2026-09-15
NMDA (N-Methyl-D-aspartic acid) is more than an excitotoxicity reagent: it can serve as a causal perturbation for connecting receptor activation, calcium influx, oxidative stress, and ferroptosis. This guide translates a recent retinal glaucoma study into practical assay-design decisions.
-
LY294002: From PI3K Inhibition to Assay Logic
2026-09-14
LY294002 is a reversible class I PI3K inhibitor for dissecting Akt/mTOR signaling, apoptosis, and autophagy. This article uses a microglial Aβ study to show how temporal controls, genetic validation, and orthogonal readouts can prevent overinterpreting pathway-inhibitor data.
-
PX-478 2HCl: From Hypoxia to Neural Assays
2026-09-14
PX-478 2HCl is an experimental HIF-1α inhibitor for connecting hypoxia signaling with cancer and neurodevelopmental assays. This guide focuses on temporal study design, multimodal readouts, and the translational limits revealed by a prenatal hypoxia rat study.
-
PBA-Modified PAD4 Inhibitors Suppress Tumor NETs
2026-09-13
The reference study developed phenylboronic acid-modified PAD4 inhibitors to improve tumor targeting while interrupting the PAD4–H3cit–NET pathway. Compound 5i reduced tumor growth and lung metastasis in mouse models, with selective cellular uptake and a favorable preliminary safety profile.
-
Phosphatase Inhibitor Cocktail 3 for Bone Signaling
2026-09-12
Phosphatase Inhibitor Cocktail 3 supports protein phosphorylation preservation when studying FAK-dependent alveolar bone formation. This article translates a mechanistic bone study into practical sample-handling and phosphoprotein analysis decisions.
-
Cabazitaxel (XRP6258) Workflow Guide
2026-09-12
Cabazitaxel (XRP6258, SKU B2157) is a dossier-supported semi-synthetic taxane derivative for studying microtubule dynamics disruption and antiproliferative responses in P-glycoprotein-expressing or taxane-resistant cancer models. It is suitable for controlled DMSO- or ethanol-based workflows, not water-based preparation, and should be used promptly after solution preparation.
-
Anlotinib Hydrochloride: Assay Design Beyond Potency
2026-09-11
Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor with coordinated activity against VEGFR2, PDGFRβ, and FGFR1. This article presents an assay-centered framework for connecting endothelial function, receptor phosphorylation, ERK signaling, and pharmacokinetic context in cancer research.
-
COX-2 in Venom-Induced Muscle Revascularization
2026-09-11
The reference study shows that COX-2 has time-dependent effects after Bothrops asper venom injury: its early activity helps preserve perfusion, whereas later inhibition can enhance angiogenic and matrix-remodeling responses. These findings position selective COX-2 inhibition as a mechanistic tool whose timing is as important as its selectivity in skeletal muscle ischemia and repair models.
-
Dexamethasone (DHAP) for Reliable Cell Assays
2026-09-10
This scenario-driven guide shows how Dexamethasone (DHAP), SKU A2324, can improve interpretation of viability, proliferation, inflammation, and differentiation experiments through disciplined formulation and controls. It connects product-handling data with practical assay design while separating documented evidence from workflow recommendations.
-
NS1–DNMT1 Control of HBoV1 Replication
2026-09-10
A 2024 PLOS Pathogens study identifies DNMT1-dependent methylation as a regulator of human bocavirus 1 replication and RNA processing. Its central innovation is the finding that the viral NS1 protein promotes DNMT1 degradation through the ubiquitin–proteasome pathway, creating a mechanistic link between viral DNA synthesis, transcript maturation, and protein expression.
-
FGFR3 Inhibition in SLC26A2 Chondrodysplasia
2026-09-09
The reference study combines genetic models, inducible postnatal deletion, chondrocyte assays, and pharmacological intervention to show that excessive FGFR3 signaling contributes to SLC26A2-related skeletal dysplasia in mice. Its findings support FGFR3 pathway inhibition as a research direction for improving chondrocyte differentiation, survival, and bone microarchitecture, while human efficacy and dosing remain unresolved.